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Background: Stanniocalcin 2 (STC2) is overexpressed in several types of human cancers, and its overexpression
positively correlates to tumor progression and poor prognosis. However, the clinical significance of STC2
overexpression in nasopharyngeal carcinomas (NPC) has not been investigated. This study examined STC2
expression in a cohort of 94 NPC samples, and explored its value in clinical diagnosis and prognosis.
Methods: Tumor samples from 94 patients diagnosed in 2008 were studied. All samples were obtained prior to
treatment start. All cases were clinically diagnosed and pathologically confirmed to be poorly differentiated or
undifferentiated NPC without distant metastasis, and have been treated with radical radiation therapy and
followed-up for five years. Survival analyses were performed.
Results: Of the 94 NPC samples, STC2 overexpression (STC2+) was detected in 65 samples (69.1%). Overall survival
rate of STC2 (+) patients is significantly lower than that of patients with normal STC2 levels (72.2% vs. 96.4%,
respectively, P = 0.049). Moreover, STC2 (+) is also strongly predictive of a low progression-free survival and distant
metastasis-free survival (63.0% vs 92.9%. P = 0.007; and 77.0% vs 96.4%. P = 0.028). Of the 54 patients treated with
IMRT, residual tumors were found in 54.8% of STC2 positive patients (17/31), but only in 17.4% of STC2 negative
ones (4/23), suggesting STC2 overexpression predicts a higher risk of residual tumors after IMRT.
Conclusions: STC2 overexpression correlates to poor prognosis for NPC and may be useful as a novel biomarker to
predict NPC responses to radiation. Whether STC2 promotes NPC progression and metastasis remains to be investigated.
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MetastasisBackground
Nasopharyngeal carcinoma (NPC) is the most commonly
diagnosed head and neck malignancy in Southeast Asia.
The standard treatment for NPC is radiotherapy alone for
early (T1N0) disease, and combined radiotherapy and
chemotherapy for more advanced lesions, including those
with nodal involvement or T2–4 disease [1,2]. Recent* Correspondence: nianli.sang@drexel.edu; panjianji@126.com
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unless otherwise stated.results from conventional radiotherapy reported an overall
survival rate (OSR) and locoregional control rate (LRCR)
of 60-67% and 58-75%, respectively [3-7]. The adoption of
intensity-modulated radiotherapy (IMRT) and combined
chemoradiotherapy (CRT) has substantially improved
the clinical outcomes. Results from prospective and
retrospective studies have confirmed the efficacy of
IMRT, and the reported LRCR of all T- and N-cases
combined exceed 90%; distant metastasis becomes the
main cause of treatment failure [8]. In addition, how
to improve the quality of life by avoiding unnecessary
dose of radiation also becomes an imminent question.
Therefore, predicting of the risk of distant metastasis
and patients’ response to treatment is important for the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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currently no reliable prognostic marker is available to
predict treatment response and guide treatment.
Solid tumors frequently develop a microenvironment
characterized by hypoxia and low glucose and glutamine
supply, which contributes to gene expression reprogram-
ming. Encoding a member of the stanniocalcin secreted
glycoprotein family, STC2 is among the most upregulated
genes in response to glutamine or glucose deprivation
[10], and it also has been found to be upregulated under
hypoxia, endoplasmic reticulum stress and radiation
[11-15]. It has been proposed that STC2 overexpression
(STC2+) contributes to tumor cell’s adaptation to such
stress conditions, thus facilitating tumor progression [10].
It has been reported that STC2 expression was upregu-
lated in various tumors, including breast cancer [16,17],
prostate cancer [18], esophageal squamous cell carcinoma
(ESC) [19], gastric cancer [20], colorectal cancer [21],
renal cell carcinoma (RCC) [22] and neuroblastoma
[23]. Clinical and pathological studies reveal that STC2
overexpression correlates to advanced tumor grade, tumor
invasiveness, metastasis and poor prognosis in prostate
cancer, ESC, gastric cancer, colorectal cancer and RCC [18].
Recently, it has also been reported that upregulated STC1,
the homologue of STC2, correlates to poor prognosis in
other tumors [24]. However, the expression status of STC2
and its clinical significance in NPC have not yet been
investigated. We examined the STC2 expression levels in a
cohort of 94 NPC samples obtained from patients prior to
treatment, and carried out a retrospective study to evaluate
the value of STC2 overexpression as a novel biomarker of
NPC prognosis and response to radiation therapy.
Materials and methods
NPC samples and patients
The studied cohort includes 94 paraffin-embedded NPC
samples from patients diagnosed between January and
December in 2008 in Fujian Provincial Cancer Hospital,
China. All cases were clinically diagnosed and confirmed
pathologically as poorly differentiated or undifferentiated
primary NPC without distant metastasis at the time of
diagnosis. Pretreatment evaluation consisted of a complete
history and physical examination, flexible fiberoptic
endoscopic examination, complete blood counts, blood
chemistries, urinalysis, chest X-ray, electrocardiogram,
magnetic resonance imaging (MRI) scans of the head and
neck, bone emission computed tomography (ECT) scans,
ultrasound of liver and abdominal lymph nodes, and dental
evaluation. Positron emission tomography (PET) scans,
CT scans of the chest and abdomen were performed when
clinically recommended.
All procedures were conducted in accordance with the
Helsinki declaration, and with approval from the Ethics
Committee of Fujian Provincial Cancer Hospital. Writteninformed consent was obtained from all participants. All
cases with a Karnofsky performance status score of more
than 70 were given informed consent prior to study entry.
All included cases were reclassified according to the
2010 American Joint Committee on Cancer (AJCC,
7th edition). Tumor samples are obtained from 68 male
and 26 female patients, with a median age of 49 year old
(range 12–79). All tumor samples were obtained by biopsy
prior to radiotherapy or chemoradiation therapy.
Immunohistochemical staining
Immunohistochemical staining was carried out to
determine the expression levels of STC2 protein.
Sections (3 ~ 4 μm) were obtained from formalin-fixed,
paraffin-embedded NPC samples from archive and
mounted on pathological slides. Routinely deparaffinized
in xylene and rehydrated in decreasing concentrations of
ethanol to water. Antigen retrieval was achieved by boiling
samples at 100°C in citrate buffer solution (Maixin_bio
MVS-0101) (pH 6.0) for 10 min. The endogenous
peroxidase activity was blocked by incubating sections
with blocking agent (Maixin, KIT-9709/9719) for 10 min.
Each slide was incubated with normal rabbit serum for
10 min at room temperature. The slides were incubated
with goat anti-human STC2 antibody (1:30, R&D Systems,
Inc., Minneapolis, MN 55413, USA). After washing with
PBS, sections were incubated with biotin-labeled rabbit
anti-goat secondary antibody at room temperature for
10 min followed by incubating with streptavidin-peroxidase
for 10 min. Diaminobenzidine was used as the final
chromogen, and hematoxylin was used for counter-staining.
Radiotherapy and other treatment
Two-dimensional conventional radiation therapy (2D-RT)
was utilized for 40 patients. Patients were simulated and
treated supinely with a customized head shell, in 1.8 or
2 Gy daily fractions, five fractions per week for 7–8 weeks.
Phase 1 consisted of two large parallel-opposed lateral
faciocervical fields treating to 36–40 Gy. The fields were
then taken off-cord to 50 Gy, with bilateral posterior neck
matching nasopharynx dose to a total of 68–72 Gy using
an anterior and two lateral fields. Node negative patients re-
ceived 50–54 Gy to the neck, whereas the doses for node
positive patients were boosted to 64–70 Gy at the involved
nodal region. The cumulative doses to the primary lesions
ranged from 60 to 80 Gy.
The other 54 patients were treated primarily with IMRT
according to an IRB-approved institutional treatment
protocol [25]. The gross tumor volumes (GTVs) of
primary and nodal masses were obtained by CT and/or
MRI. The high-risk clinical tumor volume (CTV) included
the GTV plus 5–10 mm margin, encompassing the entire
nasophryngeal mucosa plus 5 mm sub-mucosal volume.
CTV for potentially involved regions included the posterior
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fossae, posterior ethmoid sinus, parapharyngeal space, skull
base, anterior third of the clivus and cervical vertebra, infer-
ior sphenoid sinus and cavernous sinuses and the retro-
pharyngeal lymph nodal and regions from the base of skull
to the cranial edge of the second cervical vertebra. CTV of
the neck nodal regions were outlined according to the rec-
ommendations by the consensus CTV delineation protocol
for head and neck malignancies. An additional 3-mm mar-
gin was added to create the planning tumor volume (PTV).
Brainstem, spinal cord, parotid glands, optic nerves, chiasm,
lens, globes, temporal lobes, temporomandibular joints,
mandible and pituitary gland were contoured and set as
organs at risk during optimization. Cumulative doses of the
primary lesion ranged from 69.2 to 75.25 Gy.
Ten patients out of 40 treated with 2D-RT and 22 out of
54 treated with IMRT had residual tumors after the com-
pletion of external beam radiation. A boost of 6–10 Gy was
delivered using intracavitory brachytherapy, conventionally
planned external beam radiation or IMRT to achieve
tumor free status. Finally, a total of 71 patients received
neoadjuvant, concurrent or adjuvant chemotherapy.
Patient follow-up
All cases involved in this study have been followed up
with established protocol till now or decease. Briefly,
after the completion of therapy, patients were followed up
at 3-month intervals during the first 2 years, at 6-month
intervals from year 2 though year 5, and annually thereafter
or till deceased. Each follow-up includes flexible fiber optic
endoscopy, basic serum chemistry, chest X-ray and
ultrasound of liver and abdomen. Either CT or MRI of the
head and neck was performed after the completion of
treatment and then every 6 months. The median follow-up
time was 51.9 months (range, 2.1-65.6 months).
Statistical analyses
Statistical analyses were carried out by using the SPSS stat-
istical software package, version 18.0 (SPSS, Inc, Chicago,
IL, USA). Comparisons of the distributions of clinical stages
and socio-demographic of different STC2 expression
groups were performed using chi-square test. Overall sur-
vival (OS), progression-free survival (PFS), locoregional
relapse-free survival (LRRFS), distant metastasis-free sur-
vival (DMFS) were plotted with the Kaplan-Meier method.
Multivariate analysis using the Cox semiparametric method
(proportional hazard model) was performed. P < 0.05 was
considered statistically significant.
Results
Establishing the standard procedures and criteria of STC2
overexpression
To establish the criteria and standards to score STC2
expression, we first stained randomly selected NPCslides to optimize the staining conditions and procedures.
From this pilot study, we noticed that some tumor adjacent
nasopharyngeal epithelia with normal morphology may
have basal levels of STC2 expression (Figure 1). After
setting the standard staining protocol, we stained all
slides under the same condition, and used normal
epithelia on slides stained under the same condition
as internal control, and the expression levels of STC2 were
scored by assessing both staining intensity and percentage
of positive cell population. Brown granular staining in cells
with higher intensity than normal epithelial cells was
considered as positive staining (overexpression). Considering
the heterogeneity of tumor tissues, the immunoreactive
scores of STC2 staining were calculated as reported pre-
viously [26]. Briefly, we scored the staining intensity as: no
staining (score 0), weak (score 1), moderate (score 2) and
strong (score 3) (Figure 2). Percentage of positive cells was
graded as following: 0–10% (grade 1), 10.1–50% (grade 2),
50.1–75% (grade 3) and 75.1–100% (grade 4). The product
of intensity score and the percentage grade was used to rep-
resent the overall positivity index. Finally, we experientially
defined overall positivity index 0–3 as negative and ≥4 as
positive for STC2 overexpression at protein levels.
STC2 overexpression is associated with NPC
Using this set of criteria and standards, we first addressed
if STC2 overexpression was associated with NPC.
Immunohistochemically stained sections were scored
independently by two pathologists blinded to the clinical
parameters. Among all primary tumor samples, 56 samples
had both tumor and normal epithelial tissues on the same
slides. The STC2 expression levels in both tumors and
adjacent normal nasopharyngeal epithelial tissues were
scored and positive index was calculated. Of these 56
tumor samples, the positive rate of STC2 in tumor tissues
is 75.0% (42/56), and that in corresponding adjoining
normal nasopharyngeal epithelial is 46.4% (26/56) (χ2 =
9.583, P = 0.002). When the total 94 NPC samples were
taken into consideration, 65 were found to be STC2
positive, giving a positive rate of 69.1% (Table 1). These
observations suggest that STC2 overexpression is
associated with NPC, but is not exclusive to tumor cells.
Correlation between STC2 overexpression and clinical
parameters
To understand if STC2 expression levels in NPC correlate
to some common clinical parameters, we grouped the
samples based on different clinical parameters. We found
that there was no significant correlation of STC2 positivity
to gender, age, N classification, or clinical stages (Table 2).
However, STC2 positive rate was higher in T3-4 than
T1-2 with a marginal significance (P=0.050), indicating
STC2 overexpression may be positively associated with
increased tumor sizes.
Figure 1 STC2 expression in tumor adjacent nasopharyngeal epithelia with normal morphology and carcinoma cells as determined by
immunohistochemistry studies. A: STC2 expressed in local tumor (× 200). B: Traditional HE staining, NPC, (× 200). C: STC2 was overexpressed in
the tumor zone (× 100). D: Negative Control: NPC tissue stained at the same conditions except that no specific antibody (anti-STC2) was added
(× 100). Scale bar: 50 μm in A and B; 100 μm in C and D.
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In the cases included in this study, the choice of initial
treatment was made by physicians’ recommendation and
patients’ preference. As a retrospective study, we
explored whether STC2 overexpression correlated to
NPC sensitivity to radiation therapy, which is the
primary choice of treatment for NPC currently. Upon
completion of radiation therapy, disregarding the
therapeutic modals, residual tumors were found in 38.5%
of STC2 positive NPC (n = 65), but only 24.1% in STC2
negative cases (n = 29) (Additional file 1: Table S1).
However, based on current sample size, this difference is
not statistically significant. Considering the samples from
patients treated with 2D-RT had an STC2 overexpression
rate much higher than that from patients treated with
IMRT (P = 0.004; Additional file 1: Table S1), we further
analyzed the correlation between STC2 status and the
presence of residual tumors after completion of IMRT. Of
the 54 patients who received IMRT, residual tumors were
found in 54.8% of STC2 positive patients (17/31),
while 17.4% of STC2 negative ones (4/23). Statisticalanalysis indicates a significant difference (P = 0.014;
Table 3), suggesting STC2 positivity predicts a higher
rate of residual tumors after IMRT.
Correlation between STC2 overexpression and five-year
outcome of NPC
Four metrics are currently used clinically to describe the
outcomes of NPC: overall survival (OS), progression-free
survival (PFS), locoregional free survival (LRRFS) and
distant metastasis-free survival (DMFS). The 5-year OS
rate of the whole cohort was 80.3%, and PFS, LRRFS and
DMFS were 72.4%, 85.7% and 83.0%, respectively. When
compared with STC2 (+) group, the STC2 negative
group had significantly higher OS, PFS and DMFS;
while LRRFS showed no statistically significant difference
(Figure 3, and Table 4).
Comparative analyses of STC2 overexpression and other
parameters in NPC prognosis
Potential prognostic factors, including gender, age, T
classification, N classification, clinical stage, the use of
chemotherapy, radiotherapy modality, presence of residual
Figure 2 Criteria for STC2 expression intensity scoring. Representative micrographs were shown as labelled (× 200). All micrographs were
taken and processed at identical conditions. Scale bar: 50 μm.
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logrank test, as shown in Table 5, where numbers of events
indicate failed cases regarding established censoring
criteria. Statistical analyses show that neither T classifica-
tion nor N classification has prognostic value for OS, PFS,
LRRFS and DMFS. On the other hand, clinical stage was
found to be a potential predictor for OS (P = 0.004), butTable 1 STC2 positivity in NPC and adjacent
nasopharyngeal epithelia
Groups STC2 positive STC2 negative χ2 P
Tumor cells 42 (75.0%) 14 (25%) 9.583 0.002
Adjacent epithelia 26 (46.4%) 30 (53.6%)not for PFS, LRRFS and DMFS. Importantly, patients in
STC2 negative group showed higher OS, PFS and DMFS
than STC2 positive group (P = 0.049, 0.007 & 0.028,
respectively), suggesting STC2 overexpression is positively
correlated to NPC progression and distant metastasis.
Univariate analyses also indicated that the addition of
chemotherapy did not benefit NPC patients in any of
the ending events censored. For the radiotherapy
modality, IMRT may improve the treatment outcomes
in regarding to OS, PFS and LRRFS (P = 0.008, 0.050, and
0.001, respectively), but does not significantly reduce DMFS
(Table 5). Finally, patients with residual tumors at the
completion of initial radiation therapy were given
additional radiation (see material and methods for
Table 2 Correlation between STC2 positivity and clinical
parameters of NPC





Gender Male 48 20 0.239 0.625
Female 17 9
Age ≤50 y 37 13 1.178 0.278
>50 y 28 16
Histology WHO* II 4 1 0.002 0.966
WHO III 61 28
T classification 1-2 16 13 3.840 0.050
3-4 49 16
N classification 0-1 36 14 0.407 0.523
2-3 29 15




*WHO, World Health Organization; Age in years (y).
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not significantly different regarding to OS, LRRFS and
DMFS, but inclined to have poor outcomes in terms
of PFS (P = 0.048).
To more accurately analyze the covariates and to avoid
the interference among variates included in this study,
we next carried out multivariate survival analyses. As
summarized in Table 6, T classification was found to be
one of the most significant prognostic factors for LRRFS
(P = 0.044), whereas N classification may affect PFS and
DMFS (P = 0.044 & 0.028 for PFS & DMFS, respectively).
Clinical stage seemed to be an independent prognostic
factor for both OS and DMFS (P = 0.002 for OS and
P = 0.037 for DMFS) (Table 6). Our Cox model also shows
that STC2 status predicts unfavorable outcome regarding
PFS and DMFS (P = 0.006 for PFS and P = 0.044 for
DMFS, respectively), clear trends of a better OS of STC-2
negative group was also noted (P = 0.059, Table 6).Table 3 Correlation between STC2 positivity and
radiation sensitivity





IMRT No 32 14 18 5.992 0.014*
Yes 22 17 5
2D-RT No 30 26 4 0.000 1.000
Yes 10 8 2
IMRT, Intensity-Modulated Radiation Therapy; 2D-RT, Two-Dimensional conventional
Radiation Therapy; Residual, Presence of residual tumors. P value showing
statistically significance was indicated by *.As detailed in Table 6, the retrospective data show that
combined chemoradiotherapy apparently resulted in a
higher DMFS than radiotherapy alone (P = 0.028). Finally,
IMRT was found to improve LRRFS and DMFS signifi-
cantly (P = 0.007 & 0.006 for LRRFS & DMFS, respectively).
Discussion
The clinical outcome of NPC has been significantly
improved since the introduction of IMRT and other new
therapies. The major obstacle for successful treatment of
NPC is that some NPC cases tend to become progressive
and distant metastasis. A better understanding of the
molecular mechanisms underlying NPC progression
and distant metastasis may nominate new therapeutic
targets. For example, a recent study focused on the
role of MTA1 in NPC progression [27]. On the other
hand, identifying prognostic biomarker may facilitate the
prediction of response prior to treatment initiation, thus
guiding the choice of treatment.
STC2 has been reported to be upregulated in a series
of cancers and been correlated to tumor progression and
prognosis [18]. It has been reported to be upregulated
in response to various stresses, including hypoxia,
endoplasmic reticulum stress, oxidative stress and radiation
[11,12,28,29]. However, whether it is overexpressed in NPC
has not been investigated. We attempt to evaluate the
expression status of STC2 and its correlation to long-term
outcomes of NPC patients. We reported that the
expression level of STC2 in primary NPC cells is
significantly higher than that in corresponding normal
nasopharyngeal epithelia. The 5-year OS, PFS and
DMFS rate of the STC2-negative group is significantly
higher than that of STC2-positive group. These results are
of particular importance, as they represent the first study
showing the expression status of STC2 in NPC may be a
potential prognostic biomarker, which may be used to
identify patients with potentially unfavorable outcomes
prior to the initiation of treatment; these patients may
benefit from a more intensive therapeutic regimen.
It has been reported that STC2 overexpression is asso-
ciated with poor prognosis or cancer recurrence in most
of the cancers studied [18]. In ovarian cancers, STC2
was one of the overexpressed genes as investigated by
immunohistochemistry-guided laser capture microdis-
section and microarray; and overexpression of STC2
was associated with a decreased disease-free interval [30].
Increased cytoplasmic STC2 expression correlated to
aggressiveness of renal cell carcinoma and shorter overall
patient survival times [22]. In colorectal cancer, it was
reported that STC2 was more frequently overexpressed in
cancerous tissues than in non-cancerous tissues, and high
mRNA expression of STC2 was significantly associated
with tumor sizes, depth, lymph node metastasis, lymphatic













Figure 3 High STC2 expression predicts inferior outcomes in NPC patients. Survival data were analyzed and plotted using the Kaplan–Meier
method. Patients were classified into STC2 negative or positive according to STC2 immunohistochemistry. *: P <0.05. A. Local regional failure-free
survival (LRFS); B. Distant metastasis-free survival (DMFS); C. Overall Survival (OS); and D. Progression-free survival (PFS).
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affecting overall survival rate by multivariate analysis [21].
In gastric cancer, patients in the high STC2 expression
group had a significantly poorer overall survival than
those in the low STC2 expression group [20]. We foundTable 4 Correlation between STC2 positivity and 5-year
outcomes





OS 72.2 96.4 3.867 0.049*
PFS 63.0 92.9 7.236 0.007*
LRRFS 82.2 92.9 1.326 0.250
DMFS 77.0 96.4 4.854 0.028*
OS, Overall survival; PFS, Progression-free survival; LRRFS, Locoregional relapse-free
survival; DMFS, Distant metastasis-free survival. P values showing statistically
significance were indicated by *.that high STC2 expression was significantly associated
with higher T classification of NPC, and STC2 was shown
to be a prognostic factor predicting poorer OS, PFS and
DMFS of NPC.
However, STC2 overexpression in breast cancers,
particularly in estrogen receptor-positive breast cancers, is
associated with favorable prognoses [16,31-33]. Estrogen
receptor-positive breast cancers are usually low-grade
malignancies and can be effectively treated with hormonal
therapies, which may explain the favorable prognosis [34,35].
Whether STC2 overexpression contributes to tumor
progression and distant metastasis remains unknown.
Tumor progression depends on accelerating the utilization,
and sustaining sufficient supply, of nutrients including
molecular oxygen, carbon source and nitrogen sources
[36,37]. Reprogrammed carbon source utilization during
tumor progression has been well known for decades; it has
Table 5 Univariate logrank analyses of prognostic parameters of NPC
Parameters Category No. of
cases
OS PFS LRRFS DMFS
Events P Events P Events P Events P
STC2 Positive 65 12 0.049* 22 0.007* 10 0.250 14 0.028*
Negative 29 1 2 2 1
Gender Male 68 11 0.190 20 0.162 10 0.336 13 0.190
Female 26 2 4 2 2
Age ≤ 50 years 50 5 0.288 11 0.371 8 0.365 5 0.083
>50 years 44 8 13 4 10
T classification 1-2 29 2 0.151 6 0.441 5 0.411 3 0.269
3-4 65 11 18 7 12
N classification 0-1 50 4 0.070 11 0.270 6 0.709 6 0.200
2-3 44 9 13 6 9
Clinical stage I 4 0 0.004* 0 0.472 0 0.781 0 0.317
II 10 0 2 2 0
III 50 4 13 6 9
IV 30 9 9 4 6
Treatment RT alone 18 4 0.360 5 0.783 1 0.324 4 0.373
CRT 76 9 19 11 11
Radiotherapy IMRT 54 3 0.008* 10 0.050* 2 0.001* 5 0.567
2D-RT 40 10 14 10 14
Residual Yes 32 4 0.875 4 0.048* 2 0.194 3 0.211
No 62 9 20 10 12
*P values showing statistically significance were indicated by *.
“Events” are numbers of failed cases regarding OS, PFS, LRRFS and DMFS.
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the utilization of glutamine [38,39]. However, solid tumors
frequently develop a microenvironment characterized by
hypoxia, low glucose and glutamine supply. As one of the
most upregulated genes in response to glutamine or
glucose deprivation, STC2 may participate in triggering
adaptive tumor metabolism, hence contributing to tumor
progression and distant metastasis [10]. However, the
precise role of STC2 in tumor progression and metastasis
remains to be investigated by further studies including
loss-of-function analysis. Nevertheless, our data show that
STC2 overexpression correlates to NPC progression, whichTable 6 Multivariate survival analyses of prognostic paramete
Parameters OS PFS
HR 95% CI P HR 95% CI
STC2 7.534 0.928-61.197 0.059 7.853 1.825-33.796
T classification 0.610 0.105-3.534 0.582 0.590 0.180-1.932
N classification 3.723 0.852-16.270 0.081 2.316 1.023-5.244
Clinical stages 6.517 2.015-21.082 0.002* 1.667 0.807-3.442
RT vs CRT 0.278 0.051-1.507 0.138 0.906 0.268-3.067
IMRT vs 2D-RT 0.351 0.077-1.597 0.176 1.085 0.422-2.792
Residual tumor 0.876 0.229-3.354 0.846 0.249 0.084-0.740
P, P values; statistically significant ones were indicated by *; HR, Hazard Ratio; 95%is consistent with previous studies in other solid tumors
[18] and with the notion that STC2 overexpression
facilitates tumor progression and migration.
In this study, we found that STC2 (+) NPC resulted in a
higher rate of residual tumors than STC2 (−) group
at the completion of initial IMRT, suggesting STC2
overexpression may contribute to tumor cell resist-
ance to radiation therapy. However, the molecular mecha-
nisms underlying the STC2 overexpression in NPC and
radiation resistance remains to be further investigated.
It has been reported [11-15] that STC2 expression is
induced by oxidative stress and hypoxia, and STC2rs of NPC
LRRFS DMFS
P HR 95% CI P HR 95% CI P
0.006* 2.080 0.347-12.484 0.423 8.065 1.056-61.572 0.044*
0.383 0.176 0.032-0.954 0.044* 0.816 0.179-3.729 0.794
0.044* 1.229 0.224-6.754 0.812 4.105 1.168-14.431 0.028*
0.167 1.161 0.337-4.003 0.813 2.596 1.066-6.323 0.036*
0.874 3.561 0.286-44.327 0.324 0.364 0.081-1.632 0.187
0.865 0.122 0.027-0.557 0.007* 5.917 1.548-22.610 0.009*
0.012* 0.771 0.153-3.895 0.753 0.113 0.025-0.505 0.004*
CI: 95% confidence interval.
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survival of ischemia nerve cells. Solid tumors frequently
develop a hypoxic condition which activates HIF-1 [40] to
sustain tumor growth and progression and STC2 is one of
HIF-1 target genes. Moreover, STC2 functions to protect
cells from apoptosis in hypoxic ovarian cancer cell lines
[11,12,28,29]. In addition to hypoxia, radiation represents
another stress and source of oxidative stress to tumor cells,
which may lead to the upregulation of STC2 following
IMRT. If proven, targeting the protective activation of
STC2 may be explored as a novel strategy to improve
radiation sensitivity.
In addition to attenuating cell proliferation and reducing
cell apoptosis, enhancing cell migration under stress
conditions by STC2 has been reported. It has been
proposed that STC2 facilitates tumor cell migration
through epithelial-mesenchymal transition (EMT) and
upregulation of MMP-2 and MMP-9 in hypoxic conditions
[14,23]. Our observation that STC2 (−) NPC patients
have a significant higher DMFS than STC2 (+) patients is
consistent with the concept that STC2 overexpression
promotes distant metastasis.
In this retrospective study, most patients received
the institutional chemotherapy regimen for NPC, and
choice of chemotherapy plans (i.e., concurrent, neoadjuvant,
adjuvant or any combination) was at the discretion of the
attending physicians. A total of 71 (75.5%) patients received
neoadjuvant chemotherapy, 34 (36.2%) and 38 (40.4%)
patients received concurrent chemotherapy and adjuvant
chemotherapy, respectively. We note that the use of
chemotherapy may influence the outcomes of treatment,
hence affecting the accuracy of data interpretation.
Carefully controlled prospective studies in the future
may complement this study.
Conclusions
In conclusion, we provide data to show that STC2 over-
expression correlates to NPC malignancy and poor prog-
nosis including higher potential of progression and distant
metastasis. STC2 overexpression may be a novel prognostic
biomarker. Its clinical value as a therapeutic target for
treatment of NPC patients remains to be investigated.
Future investigations including prospective studies are
required to further validate the value of STC2 overexpres-
sion in NPC prognosis. Laboratory animal and cell culture
studies are also required to provide mechanistic
understanding of the roles of STC2 in tumor progression,
metastasis and resistance to radiation therapy (IMRT).Additional file
Additional file 1: Table S1. STC2 overexpression status in different
treatment groups.Abbreviations
2D-RT: 2-dimensional conventional radiation therapy; CTV: Clinical tumor
volume; DMFS: Distant metastasis-free survival; ECT: Emission computed
tomography; ESC: Esophageal squamous cell carcinoma; GTV: Gross tumor
volumes; IMRT: Intensity-modulated radiotherapy; LRCR: Locoregional control
rate; LRRFS: Local regional relapse-free survival; MRI: Magnetic resonance
imaging; NPC: Nasopharyngeal carcinomas; OS: Overall survival;
PFS: Progression-free survival; PET: Positron emission tomography;
PTV: Planning tumor volume; RCC: Renal cell carcinoma; STC2: Stanniocalcin 2.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
SL participated in the design and coordination of this study, and helped
draft the manuscript. QG designed experimental protocols and drafted the
manuscript. JW carried out the Immunohistochemical staining, performed
the statistical analysis and participated in manuscript preparation. CL
participated in the data collection and Immunohistochemical staining. JL
and XC participated in the data collection. NS and JP conceived of this idea,
outlined study design, and helped manuscript preparation. All authors have
read and approved the final manuscript.
Acknowledgments
This work was sponsored by Key Clinical Specialty Discipline Construction
Program of Fujian, People’s Republic of China. Dr. Sang’s research is supported
by a grant from National Cancer Institute, NIH USA (R01-CA0129494). The
authors thank Chengqian Yin for reviewing the statistics and proofreading the
manuscript prior to submission.
Author details
1Department of Radiation Oncology, Fujian Provincial Cancer Hospital,
Fuzhou, Fujian, China. 2Provincial Clinical College, Fujian Medical University,
Fuzhou, Fujian, China. 3Fujian Provincial Key Laboratory of Translational
Cancer Medicine, Fuzhou, Fujian, China. 4Department of Pathology, Fujian
Provincial Cancer Hospital, Fuzhou, Fujian, China. 5Department of Biology
College of Arts & Sciences, Drexel University, Papadakis Integrated Sciences
Building, room 417, Philadelphia, USA. 6Department of Pathology &
Laboratory Medicine, College of Medicine, Drexel University, Philadelphia,
USA.
Received: 18 February 2014 Accepted: 3 March 2014
Published: 8 March 2014
References
1. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA,
Adams G, Sakr WA, Schuller DE, Ensley JF: Chemoradiotherapy versus
radiotherapy in patients with advanced nasopharyngeal cancer: Phase III
randomized intergroup study 0099. J Clin Oncol 1998, 16(4):1310–1317.
2. Cooper JS, Lee H, Torrey M, Hochster H: Improved outcome secondary to
concurrent chemoradiotherapy for advanced carcinoma of the
nasopharynx: Preliminary corroboration of the intergroup experience.
Int J Radiat Oncol Biol Phys 2000, 47(4):861–866.
3. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA,
Adams G, Sakr WA, Schuller DE, Ensley JF: Superiority of 5-year survival
with chemoradiotherapy vs radiotherapy in patients with locally
advanced nasopharyngeal cancer. Intergroup 0099 Phase III study: final
report [Abstract]. Proc Am Soc Clin Oncol 2001, 20:227a.
4. Hareyama M, Sakata K, Shirato H, Nishioka T, Nishio M, Suzuki K, Saitoh A,
Oouchi A, Fukuda S, Himi T: Prospective, randomized trial comparing
neoadjuvant chemotherapy with radiotherapy alone in patients with
advanced nasopharyngeal carcinoma. Cancer 2002, 94(8):2217–2223.
5. Chi KH, Chang YC, Guo WY, Leung MJ, Shiau CY, Chen SY, Wang LW, Lai YL, Hsu
MM, Lian SL, Chang CH, Liu TW, Chin YH, Yen SH, Perng CH, Chen KY: A phase
III study of adjuvant chemotherapy in advanced stage nasopharyngeal
carcinoma patients. Int J Radiat Oncol Biol Phys 2002, 52(5):1238–1244.
6. Ma J, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, Lu TX, Mo HY: Results of
a prospective randomized trial comparing neoadjuvant chemotherapy
plus radiotherapy with radiotherapy alone in patients with
locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001,
19(5):1350–1357.
Lin et al. Journal of Experimental & Clinical Cancer Research 2014, 33:26 Page 10 of 10
http://www.jeccr.com/content/33/1/267. Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, Lu TX, Min HQ:
Long-term survival after cisplatin-based induction chemotherapy and
radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of
two phase III trials. J Clin Oncol 2005, 23(6):1118–1124.
8. Wang T, Riaz N, Cheng S, Lu J, Lee N: Intensity-modulated radiation therapy
for nasopharyngeal carcinoma: a review. J Radiat Oncol 2012, 1:129–146.
9. Zaatar AM, Lim C, Bong C, Lee MM, Ooi J, Suria D, Raman R, Chao S, Yang H,
Neoh S, Liew CC: Whole blood transcriptome correlates with treatment
response in nasopharyngeal carcinoma. J Exp Clin Cancer Res 2012, 31:76.
10. Qie S, Liang D, Yin C, Gu W, Meng M, Wang C, Sang N: Glutamine
depletion and glucose depletion trigger growth inhibition via distinctive
gene expression reprogramming. Cell Cycle 2012, 11(19):3679–3690.
11. Law AY, Lai KP, Ip CK, Wong AS, Wagner GF, Wong CK: Epigenetic and HIF-1
regulation of stanniocalcin-2 expression in human cancer cells. Exp Cell Res
2008, 314(8):1823–1830.
12. Law AY, Wong CK: Stanniocalcin-2 is a HIF-1 target gene that promotes
cell proliferation in hypoxia. Exp Cell Res 2010, 316(3):466–476.
13. Ito D, Walker JR, Thompson CS, Moroz I, Lin W, Veselits ML, Hakim AM,
Fienberg AA, Thinakaran G: Characterization of stanniocalcin 2, a novel
target of the mammalian unfolded protein response with cytoprotective
properties. Mol Cell Biol 2004, 24(21):9456–9469.
14. Law AY, Wong CK: Stanniocalcin-2 promotes epithelial-mesenchymal
transition and invasiveness in hypoxic human ovarian cancer cells.
Exp Cell Res 2010, 316(20):3425–3434.
15. Collins CL, Wasa M, Souba WW, Abcouwer SF: Regulation of glutamine
synthetase in human breast carcinoma cells and experimental tumors.
Surgery 1997, 122(2):451–463. discussion 463–464.
16. Bouras T, Southey MC, Chang AC, Reddel RR, Willhite D, Glynne R,
Henderson MA, Armes JE, Venter DJ: Stanniocalcin 2 is an
estrogen-responsive gene coexpressed with the estrogen receptor
in human breast cancer. Cancer Res 2002, 62(5):1289–1295.
17. Joensuu K, Heikkila P, Andersson LC: Tumor dormancy: elevated
expression of stanniocalcins in late relapsing breast cancer. Cancer Lett
2008, 265(1):76–83.
18. Tamura K, Furihata M, Chung SY, Uemura M, Yoshioka H, Iiyama T, Ashida S,
Nasu Y, Fujioka T, Shuin T, Nakamura Y, Nakagawa H: Stanniocalcin 2
overexpression in castration-resistant prostate cancer and aggressive
prostate cancer. Cancer Sci 2009, 100(5):914–919.
19. Kita Y, Mimori K, Iwatsuki M, Yokobori T, Ieta K, Tanaka F, Ishii H, Okumura H,
Natsugoe S, Mori M: STC2: a predictive marker for lymph node metastasis
in esophageal squamous-cell carcinoma. Ann Surg Oncol 2011,
18(1):261–272.
20. Yokobori T, Mimori K, Ishii H, Iwatsuki M, Tanaka F, Kamohara Y, Ieta K, Kita Y,
Doki Y, Kuwano H, Mori M: Clinical significance of stanniocalcin 2 as a
prognostic marker in gastric cancer. Ann Surg Oncol 2010, 17(10):2601–2607.
21. Ieta K, Tanaka F, Yokobori T, Kita Y, Haraguchi N, Mimori K, Kato H, Asao T,
Inoue H, Kuwano H, Mori M: Clinicopathological significance of
stanniocalcin 2 gene expression in colorectal cancer. Int J Cancer 2009,
125(4):926–931.
22. Meyer HA, Tölle A, Jung M, Fritzsche FR, Haendler B, Kristiansen I, Gaspert A,
Johannsen M, Jung K, Kristiansen G: Identification of stanniocalcin 2 as
prognostic marker in renal cell carcinoma. Eur Urol 2009, 55(3):669–678.
23. Volland S, Kugler W, Schweigerer L, Wilting J, Becker J: Stanniocalcin 2
promotes invasion and is associated with metastatic stages in
neuroblastoma. Int J Cancer 2009, 125(9):2049–2057.
24. Song H, Xu B, Yi J: Clinical significance of stanniocalcin-1 detected in
peripheral blood and bone marrow of esophageal squamous cell
carcinoma patients. J Exp Clin Cancer Res 2012, 31:35.
25. Lin S, Pan J, Han L, Zhang X, Liao X, Lu JJ: Nasopharyngeal carcinoma
treated with reduced-volume intensity-modulated radiation therapy:
report on the 3-year outcome of a prospective series. Int J Radiat Oncol
Biol Phys 2009, 75(4):1071–1078.
26. Kummoona R, Mohammad Sámi S, Al-Kapptan I, Al-Muala H: Study of
antiapoptotic gene of oral carcinoma by using Bcl-2 oncogene. J Oral
Pathol Med 2008, 37(6):345–351.
27. Song Q, Zhang H, Wang M, Song W, Ying M, Fang Y, Li Y, Chao Y, Zhu X:
MTA1 promotes nasopharyngeal carcinoma growth in vitro and in vivo.
J Exp Clin Cancer Res 2013, 32(1):54.
28. Xu L, Pan J, Wu J, Pan C, Zhang Y, Lin S, Yang L, Chen C, Zhang C, Zheng W,
Lin S, Ni X, Kong FM: Factors associated with overall survival in 1706
patients with nasopharyngeal carcinoma: significance of intensiveneoadjuvant chemotherapy and radiation break. Radiother Oncol 2010,
96(1):94–99.
29. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW:
Sublethal irradiation of human tumor cells modulates phenotype
resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res
2004, 64(21):7985–7994.
30. Buckanovich RJ, Sasaroli D, O’Brien-Jenkins A, Botbyl J, Hammond R,
Katsaros D, Sandaltzopoulos R, Liotta LA, Gimotty PA, Coukos G: Tumor
vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 2007,
25(7):852–861.
31. Raulic S, Ramos-Valdes Y, DiMattia GE: Stanniocalcin 2 expression is regulated
by hormone signaling and negatively affects breast cancer cell viability
in vitro. J Endocrinol 2008, 197(3):517–529.
32. Yamamura J, Miyoshi Y, Tamaki Y, Taguchi T, Iwao K, Monden M, Kato K,
Noguchi S: mRNA expression level of estrogen-inducible gene, alpha
1-antichymotrypsin, is a predictor of early tumor recurrence in patients
with invasive breast cancers. Cancer Sci 2004, 95(11):887–892.
33. Esseghir S, Kennedy A, Seedhar P, Nerurkar A, Poulsom R, Reis-Filho JS,
Isacke CM: Identification of NTN4, TRA1, and STC2 as prognostic markers
in breast cancer in a screen for signal sequence encoding proteins.
Clin Cancer Res 2007, 13(11):3164–3173.
34. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ: Meeting highlights:
international consensus panel on the treatment of primary breast
cancer. Seventh international conference on adjuvant therapy of primary
breast cancer. J Clin Oncol 2001, 19(18):3817–3827.
35. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thu¨rlimann B, Senn HJ:
Progress and promise: highlights of the international expert consensus
on the primary therapy of early breast cancer. Ann Oncol 2007,
18(7):1133–1144.
36. Meng M, Chen S, Lao T, Liang D, Sang N: Nitrogen anabolism underlies
the importance of glutaminolysis in proliferating cells. Cell Cycle 2010,
9(19):3921–3932.
37. Yin C, Qie S, Sang N: Carbon source metabolism and its regulation in
cancer cells. Crit Rev Eukaryot Gene Expr 2012, 22(1):17–35.
38. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, de Marzo AM,
van Eyk JE, Mendell JT, Dang CV: c-Myc suppression of miR-23a/b enhances
mitochondrial glutaminase expression and glutamine metabolism.
Nature 2009, 458(7239):762–765.
39. Qie S, Chu C, Li W, Wang C, Sang N: ErbB2 activation upregulates
glutaminase 1 expression which promotes breast cancer cell
proliferation. J Cell Biochem 2014, 115:498–509.
40. Liang D, Kong X, Sang N: Effects of histone deacetylase inhibitors on
HIF-1. Cell Cycle 2006, 5(21):2430–2435.
doi:10.1186/1756-9966-33-26
Cite this article as: Lin et al.: Survival analyses correlate stanniocalcin 2
overexpression to poor prognosis of nasopharyngeal carcinomas.
Journal of Experimental & Clinical Cancer Research 2014 33:26.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
